About Cell adhesion molecule CEACAM16
Cell adhesion molecule CEACAM16 (CEACAM16) is a protein
from Homo sapiens identified by UniProt accession
Q2WEN9, 425 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Cell adhesion molecule CEACAM16 |
| UniProt accession | Q2WEN9 |
| Gene | CEACAM16 |
| Organism | Homo sapiens |
| Length | 425 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (62)
Diseases linked to this target (Open Targets).
- autosomal dominant nonsyndromic hearing loss · score 0.62
- hearing loss, autosomal recessive · score 0.57
- nonsyndromic genetic hearing loss · score 0.52
- ear malformation · score 0.27
- Rare genetic deafness · score 0.27
- Abnormality of the ear · score 0.27
- apolipoprotein B measurement · score 0.20
- genetic disorder · score 0.19
- Hearing impairment · score 0.16
- deafness · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q2WEN9-F1 | alphafold | PREDICTED | 90.24 | — |
Amino-acid sequence (425 residues)
MALTGYSWLL LSATFLNVGA EISITLEPAQ PSEGDNVTLV VHGLSGELLA YSWYAGPTLS VSYLVASYIV STGDETPGPA HTGREAVRPD GSLDIQGILP RHSGTYILQT FNRQLQTEVG YGHVQVHEIL AQPTVLANST ALVERRDTLR LMCSSPSPTA EVRWFFNGGA LPVALRLGLS PDGRVLARHG IRREEAGAYQ CEVWNPVSVS RSEPINLTVY FGPERVAILQ DSTTRTGCTI KVDFNTSLTL WCVSRSCPEP EYVWTFNGQA LKNGQDHLNI SSMTAAQEGT YTCIAKNTKT LLSGSASVVV KLSAAAVATM IVPVPTKPTE GQDVTLTVQG YPKDLLVYAW YRGPASEPNR LLSQLPSGTW IAGPAHTGRE VGFPNCSLLV QKLNLTDTGR YTLKTVTVQG KTETLEVELQ VAPLG
Explore Cell adhesion molecule CEACAM16 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets